BioPhorum recently created a resource of potential critical quality attributes (CQAs) for mRNA products from the early stages of drug development to commercial manufacturing. We asked two of the paper’s authors some questions to explore the key areas in more detail.
Calviri has been developing an RNA vaccine to prevent cancer for more than 20 years, and repeatedly faced the nearly universal belief that it’s impossible. We’ve learned a number of important lessons along the way that are worth imparting to other vaccine developers.
Defining A Process For Your Unique mRNA
Define a process for your unique mRNA with this interactive guide to pDNA, mRNA, and LNP. Overcome challenges with solutions that can help you develop a next-generation production strategy.